COLL · Collegium Pharmaceutical, Inc · Documents
$23.59
+0.67 (+2.92%)
At close · Oct 22
Return incl. dividend (before tax)
Market Cap
$746.01M
Shares
32.56M
Volume · Oct 22
203.15K
Avg daily vol (3M)
781.51K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Collegium Pharmaceutical and Grünenthal entered a October 15, 2026 settlement terminating the Grünenthal License after Collegium paid $17,000,000, fully discharging royalty obligations, with Grünenthal assigning Nucynta-related patents to Collegium and moving to dismiss the Nucynta Litigation. | 2026-10-19 | 2026-10-15 | |
| Investor Event Transcript | — | 2026-09-16 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| 8-K | — | 2026-08-13 | 2026-08-12 | |
| 10-Q | — | 2026-08-06 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| 8-K/A | — | 2026-06-30 | 2026-05-12 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-05-15 | 2026-05-14 | |
| 8-K | — | 2026-05-12 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| 8-K | — | 2026-05-07 | — | |
| Investor Event Transcript | — | 2026-04-15 | 2026-06-30 | |
| 8-K | — | 2026-04-07 | 2026-04-02 | |
| DEF 14A | — | 2026-04-07 | 2026-05-14 | |
| ARS | — | 2026-04-07 | 2025-12-31 | |
| Investor Event Transcript | — | 2026-03-19 | 2026-03-31 | |
| 8-K | — | 2026-03-19 | — | |
| 10-K | — | 2026-02-26 | 2025-12-31 | |
| 8-K | — | 2026-02-26 | — | |
| 8-K | — | 2026-01-08 | — | |
| 8-K | — | 2025-12-30 | 2025-12-23 | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-08-07 | — | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-07-07 | 2025-07-01 | |
| 8-K | — | 2025-05-19 | 2025-05-15 | |
| 8-K | — | 2025-05-12 | — | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| ARS | — | 2025-03-28 | 2024-12-31 | |
| DEFA14A | — | 2025-03-28 | — | |
| DEF 14A | — | 2025-03-28 | 2025-05-15 | |
| 8-K | — | 2025-03-17 | 2025-03-11 | |
| 8-K | — | 2025-02-27 | — | |
| 10-K | — | 2025-02-27 | 2024-12-31 | |
| 8-K | — | 2025-02-05 | 2025-02-03 | |
| 8-K | — | 2025-01-08 | — | |
| 8-K/A | — | 2024-11-14 | 2024-09-03 | |
| 8-K | — | 2024-11-07 | 2024-11-06 | |
| 10-Q | — | 2024-11-07 | 2024-09-30 | |
| 8-K | — | 2024-09-04 | 2024-09-03 | |
| 8-K | — | 2024-08-08 | — | |
| 10-Q | — | 2024-08-08 | 2024-06-30 | |
| 8-K | — | 2024-07-29 | 2024-07-28 | |
| 8-K | — | 2024-06-13 | — | |
| 8-K | — | 2024-05-24 | — | |
| 8-K | — | 2024-05-20 | 2024-05-16 | |
| 8-K | — | 2024-05-13 | — |
Showing 1–50 of 141 filings
Key facts
CIK
1267565
CUSIP
19459J104
13F (30d)
22 filings
22 filers
Visit website
Investor relations